Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “United Kingdom”

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruiting
NCT06743126Phase 3Updated Aug 18, 2026
Sponsor: Immatics US, Inc.
Melanoma, Cutaneous Malignant
United States, Canada, France, Germany, Netherlands +1 more
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.Recruiting
NCT05948943Phase 2, Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Lymphatic Malformations
United States, Argentina, Australia, Belgium, Czechia +7 more
An Observational Clinical Study to Collect Photographic Data of Wounds With Hypergranulation to Aid Development of a Hypergranulation Clinical Endpoint and Assessment Tool, And Generate Participant Reported Data to Inform Trial DesignTerminated
NCT07334717N/AUpdated Aug 18, 2026
Sponsor: Ennogen Healthcare Limited
Wound Complications
United Kingdom
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruiting
NCT07415031Phase 2Updated Aug 18, 2026
Sponsor: Mirati Therapeutics Inc.
Solid Tumors
United States, Australia, Belgium, Canada, China +15 more
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive Not Recruiting
NCT03732820Phase 3Updated Aug 18, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Belgium, Brazil, Canada +12 more
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Recruiting
NCT07486934Phase 3Updated Aug 18, 2026
Sponsor: Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Steinert Disease
United States, Belgium, Denmark, France, Germany +5 more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)Terminated
NCT05665595Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Argentina, Australia, Austria, Belgium +21 more
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLCRecruiting
NCT07718243Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Institute of Cancer Research, United Kingdom
Melanoma (Skin Cancer) · Non Small Cell Lung Cancer · Solid Tumor in Advanced Stage
United Kingdom
Neonatal Enhanced Recovery After Surgery (ERAS) Outcomes StudyNot Yet Recruiting
NCT07771478N/AUpdated Aug 18, 2026
Sponsor: The Hospital for Sick Children
Neonatal Patients Undergoing Major Non-cardiac Surgery · Congenital Anomaly
Canada, United Kingdom
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisRecruiting
NCT07201922Phase 3Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Familial Pulmonary Fibrosis · Interstitial Lung Abnormalities · Interstitial Lung Diseases
United States, Argentina, Australia, Belgium, Canada +8 more
EMG-Directed Virtual-Reality Training for Motor Stroke RehabilitationNot Yet Recruiting
NCT07705256NAUpdated Aug 18, 2026
Sponsor: Imperial College London
Stroke · Spinal Cord Injuries (Complete and Incomplete)
United Kingdom
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)Recruiting
NCT06997588Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Australia, Austria, Belgium, France +5 more
A Phase I Trial of LY3143921 Hydrate in Solid TumoursCompleted
NCT03096054Phase 1Updated Aug 18, 2026
Sponsor: Cancer Research UK
Colorectal Cancer · High Grade Serous Ovarian Cancer · Non Small-cell Lung Cancer (Squamous Cell Variant) · Urothelial Cancer
United Kingdom
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active Not Recruiting
NCT05156281Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
United States, Argentina, Brazil, Bulgaria, Canada +22 more
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic ImpairmentRecruiting
NCT07422610Phase 1Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Advanced Malignancies and Hepatic Impairment
France, Italy, Spain, United Kingdom
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)Active Not Recruiting
NCT06963710Phase 2Updated Aug 18, 2026
Sponsor: Aligos Therapeutics
Chronic Hepatitis B Infection
United States, Bulgaria, Canada, China, France +9 more
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the InvestigatorCompleted
NCT01742299Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
GIST and CML
United States, China, Finland, France, Hong Kong +6 more
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)Completed
NCT04880434Phase 2Updated Aug 18, 2026
Sponsor: Kite, A Gilead Company
Relapsed/Refractory Mantle Cell Lymphoma
United States, France, Germany, Netherlands, Spain +1 more
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCDRecruiting
NCT05431088Phase 2, Phase 3Updated Aug 18, 2026
Sponsor: Pfizer
Sickle Cell Disease
United States, Brazil, India, Kenya, Nigeria +2 more
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast CancerRecruiting
NCT06888388N/AUpdated Aug 18, 2026
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Breast Cancer Surgery
United States, Australia, Belgium, Canada, Japan +3 more
Mifepristone Outpatient Labour InductionRecruiting
NCT05177510Phase 2Updated Aug 18, 2026
Sponsor: Chelsea and Westminster NHS Foundation Trust
Labor, Induced
United Kingdom
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility StudyActive Not Recruiting
NCT05653193Phase 2Updated Aug 18, 2026
Sponsor: Manchester University NHS Foundation Trust
Chronic Pulmonary Aspergillosis · Aspergillosis
United Kingdom
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active Not Recruiting
NCT03616587Phase 1Updated Aug 18, 2026
Sponsor: AstraZeneca
ER+ HER2- Advanced Breast Cancer
United States, Spain, United Kingdom
Study of the Effects of Atomoxetine on MotivationNot Yet Recruiting
NCT07771595Phase 4Updated Aug 18, 2026
Sponsor: University of Oxford
Apathy
United Kingdom

Previous page Next page